2020 News November 16, 2020 Nymox Provides Updat
Post# of 31
(Total Views: 226)
Posted On: 11/16/2020 3:03:14 PM
2020 News
November 16, 2020
Nymox Provides Update on Regulatory Filing Activities
Nymox Pharmaceutical Corporation is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.
Download
August 12, 2020
Nymox Announces $9 Million Registered Direct Offering
Nymox Pharmaceutical Corporation today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock.
Download
July 28, 2020
NYMOX Provides Current Update on Key Company Developments
Nymox Pharmaceutical Corporation is pleased to report current updates on the Company's most important ongoing developments.
Download
June 19, 2020
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
Nymox Pharmaceutical Corporation is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track.
Download
April 21, 2020
Nymox Announces Important New Patent Developments
Nymox Pharmaceutical Corporation is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments.
Download
February 24, 2020
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
Nymox Pharmaceutical Corporation is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.
Download
February 6, 2020
Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs
Nymox Pharmaceutical Corporation is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.
Download
January 28, 2020
Nymox Provides Update on Current Corporate Activities and Milestones
Nymox Pharmaceutical Corporation is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.
Download
January 6, 2020
Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology
Nymox Pharmaceutical Corporation is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.
November 16, 2020
Nymox Provides Update on Regulatory Filing Activities
Nymox Pharmaceutical Corporation is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.
Download
August 12, 2020
Nymox Announces $9 Million Registered Direct Offering
Nymox Pharmaceutical Corporation today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock.
Download
July 28, 2020
NYMOX Provides Current Update on Key Company Developments
Nymox Pharmaceutical Corporation is pleased to report current updates on the Company's most important ongoing developments.
Download
June 19, 2020
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
Nymox Pharmaceutical Corporation is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track.
Download
April 21, 2020
Nymox Announces Important New Patent Developments
Nymox Pharmaceutical Corporation is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments.
Download
February 24, 2020
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
Nymox Pharmaceutical Corporation is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.
Download
February 6, 2020
Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs
Nymox Pharmaceutical Corporation is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.
Download
January 28, 2020
Nymox Provides Update on Current Corporate Activities and Milestones
Nymox Pharmaceutical Corporation is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.
Download
January 6, 2020
Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology
Nymox Pharmaceutical Corporation is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.
(0)
(0)Nymox Pharmaceutical Corp. (NYMX) Stock Research Links
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.